Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSURE-1: IMU-838 in Relapsing Multiple Sclerosis
NCT05134441Phase 3Active, not recruiting
- Sponsor
- Immunic Therapeutics
- Start
- Nov 2021
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3 trial, sponsored by Immunic Therapeutics. Started Nov 2021; status: active, not recruiting.
Beyond the preview
Go deeper on NCT05134441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134441.